Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 + dolutegravir as a. 2-drug regimen in treatment-naive adults: 24-week results from the Phase IIb DYNAMIC study

Authors
Category Primary study
Conference19th European AIDS Conference (#EACS2023)
Year 2023
This article has no abstract
Epistemonikos ID: eaaf25f02dd91f9f41c83b7212a87b9500377c74
First added on: Apr 14, 2026